Cardiomyopathies, AMI (STEMI) (Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting with ST-Segment Elevation), Pocket guideline, Metabolic drug in pts with Stabile Angina” trial (2004-2006), Metabolic drug in pts with ACS” trial (2005-2007), Platelet inhibitors for prevention of vascular events in patients with non-ST and ST elevation ACS (2007-2009), Antiplatelet treatment is patients with ACS (2007-2010), Platelet inhibitors for prevention of vascular events in patients with non-ST and ST elevation ACS (2007-2009), Anti-inflammatory drug with Antilipidemic treatment in patients with ACS (2008-2010), Antiplatlet treatment is patients with ACS, who require PCI (2008-2010), Anti-inflammatory drug with Antilipidemic treatment in patients with ACS (2010-2011), Cangrelor versus standard Therapy to Achieve Optimal Management of Platelet InhibitiON (2011-2012), Randomized, Double-Blind,Placebo, contrived, paqrallel study of Ranolazine in subjects with cronic stable angina and coronary artery disease with a history of type 2 Diabetes mellitus (2012-2012), Study assessing the morbi-mortality benefits of the if inhibitors ivabradine in patients with coronary artery disease (2012-2013), A Randomized,Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Melltus (2013-2017), Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatmnent with Ertugliflozin in Subjects with Type 2 Diabetes Mellitus and Established Vascular Disease, The Vertis CV Study (2015-present), Relypsa RLY5016-207 (AMBER)- A Randomized, Duble-Blind, Placebo-controlled, Parallel Group Study of Patiromer for the Enablement of Spirinolactone Use for Blood Pressure Control in Patients with Resistant Hypertension of Safety and Efficacy. (2017-present), Vifor (AFFIRM-AHF) (2019-present), Basilia ceftobiprole medocaril (2019- present), TRICIDA-TRCA-303 (2019-present), Windows, MS office, Internet, Email